Vertaling van "higher " (Frans → Nederlands) :

Return to higher care-DEF (.PDF)
Return to higher care-DEF (.PDF)

Des données favorables provenant des études ALOFT (insuffisance cardiaque) et AVOID (maladies rénales), qui font partie du programme ASPIRE HIGHER qui explore les bénéfices du médicament en termes de protection cardiaque et rénale, ont été ajoutées à l’information du produit en Europe.
Positive data from the ALOFT (heart failure) and AVOID (kidney disease) clinical studies, which are part of the ASPIRE HIGHER cardio-renal outcomes program, were added to European product information.

Les données du programme de résultats ASPIRE HIGHER et diverses associations avec d’autres médicaments en un comprimé unique devraient soutenir sa croissance future.
Data from the ASPIRE HIGHER outcomes program and various single-pill combinations with other medicines are expected to drive future growth.

31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus
31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer

Quiet machinery – Higher competitiveness and better health BE Brussels, 18/06/2013
Quiet machinery – Higher competitiveness and better health BE Brussels, 18-06-2013

4/2785 1-3 y Vertebral # RR= 0.55 (95% CI 0.43-0.69) NNT 20-42 (lower in higher risk groups)
1-3 y Vertebral # RR= 0.55 (95% CI 0.43-0.69) NNT 20-42 (lower in higher risk groups)

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.

Gestation increased by 6.0 +/- 2.3 days (P =.009) in the higher
Gestation increased by 6.0 +/- 2.3 days (P =.009) in the higher docosahexaenoic

Les auteurs ont également exprimé leur inquiétude devant cette mortalité cardiovasculaire accrue (‘The higher rate of fatal cardiovascular events with olmesartan . is of concern’).
De auteurs tonen zich eveneens bezorgd over deze verhoogde cardiovasculaire mortaliteit (‘The higher rate of fatal cardiovascular events with olmesartan . is of concern’).

5/5376 1-3 y Hip # RR= 0.47 (95% CI 0.26-0.85) NNT 22-100 (lower in higher risk groups)
1-3 y Hip # RR= 0.47 (95% CI 0.26-0.85) NNT 22-100 (lower in higher risk groups)